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cardiotoxicity in breast cancer patients with
adjuvant trastuzumab therapy
Kenichi Katsurada1, Masaru Ichida1*, Masako Sakuragi2, Megumi Takehara2, Yasuo Hozumi2 and Kazuomi Kario1Abstract
The humanized monoclonal antibody trastuzumab has been in routine use for chemotherapy for human epidermal
growth factor receptor II (HER2)-positive breast cancer. A major adverse effect of trastuzumab is cardiotoxicity.
Well-established biomarkers or echocardiographic parameters to predict trastuzumab-induced cardiotoxicity have
not yet been determined. We attempted to identify useful biomarkers and/or echocardiographic parameters to
predict trastuzumab-induced cardiotoxicity.
We prospectively investigated the cases of 19 women who received chemotherapy including anthracyclines and
trastuzumab for HER2-positive breast cancer. We measured cardiac biomarkers and echocardiographic parameters
before their chemotherapy and every 3 months up to 15 months until the end of the adjuvant trastuzumab
therapy.
We divided the patients into two groups: group R was the nine patients who showed a reduction of left ventricular
ejection fraction (LVEF) ≥5%, and group N was the 10 patients who showed a reduction of LVEF <5%. The high-sensitivity
troponin T (hs-TnT) level at 6 months was significantly higher in group R than in group N (11.0 ± 7.8 pg/mL vs. 4.0 ±
1.4 pg/mL, p < 0.01). The hs-TnT level with a cutoff value of 5.5 pg/mL at 6 months had 78% sensitivity and 80%
specificity for predicting a reduction of LVEF at 15 months. In our evaluation of echocardiographic parameters at
baseline, the diastolic function was more impaired in group R than in group N.
The hs-TnT and echocardiographic parameters of diastolic function could be useful to predict trastuzumab-induced
cardiotoxicity.
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Trastuzumab is a humanized monoclonal antibody that
has been in routine use for chemotherapy for human epi-
dermal growth factor receptor II (HER2)-positive breast
cancer. Several clinical trials revealed evidence that com-
bination therapy with trastuzumab and anthracyclines im-
proved the survival rate of patients with HER2-positive
breast cancer, which is detected in 20% to 30% of all breast
cancers and has both a poor prognosis and a high risk of
recurrence (Hudis 2007). However, a known major ad-
verse effect of trastuzumab is cardiotoxicity, which can* Correspondence: bcichida@jichi.ac.jp
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in any medium, provided the original work is pcause the development of heart failure and necessitate the
withdrawal of a therapeutic agent for breast cancer (Chen
et al. 2008). The assessment of a reduction of the ven-
tricular ejection fraction (LVEF) by echocardiography or
cardiac scintigraphy has been used to detect trastuzumab
induced-cardiotoxicity. It is an important issue to eluci-
date the markers to predict trastuzumab-induced cardio-
toxicity before which show a reduction of LVEF.
Several reports showed that plasma concentration of
high-sensitivity troponin I (hs-TnI) or a myocardial strain
measured by echocardiography correlates with the risk of
trastuzumab-induced cardiotoxicity, and thus the mea-
surement of these parameters may be able to predict
cardiotoxicity (Sawaya et al. 2011, 2012; Fallah-Rad et al.
2011). However, specific biomarkers or echocardiographicis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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remains to be established.
In this study, we prospectively investigated whether
cardiac biomarkers and/or echocardiographic parame-
ters predict the incidence of trastuzumab-induced car-
diotoxicity, and we compared the operating characteristics
of these parameters with those reported before.
Methods
Study design and patient selection
Twenty women with HER2-positive breast cancer and
scheduled to receive adjuvant chemotherapy including
anthracyclines, taxanes and trastuzumab at Jichi Medical
University Hospital between June 2010 and March 2012
were prospectively enrolled. The patient population was
evaluated before chemotherapy and every 3 months up
to 15 months until the end of trastuzumab therapy: be-
fore the initiation of anthracycline therapy (at baseline),
the completion of the anthracycline therapy (before the
initiation of trastuzumab therapy: at 3 months), and at 6,
9, 12 and 15 months. At each time point, cardiac bio-
markers and echocardiographic parameters were mea-
sured (Figure 1).
In accordance with the guideline of the Cardiac Review
and Evaluation Committee for trastuzumab-associated
cardiotoxicity, we defined trastuzumab-induced cardio-
toxicity as a reduction of LVEF ≥5% to <55% with symp-
tomatic heart failure or an asymptomatic reduction of
LVEF ≥10% to <55%. Because none of the present 20 pa-
tients showed cardiotoxicity in accordance with this defin-
ition, we defined cardiac damage as a reduction of LVEF
≥5%, and we divided the patients into two groups: group
R (reduction of LVEF ≥5%) and group N (reduction of
LVEF <5%) for analysis. The Ethics Committee of Jichi
Medical University approved the study protocol. All pa-
tients enrolled in this study provided informed consent.
Measurement of biomarkers
The biomarkers assessed in this study were high-
sensitivity troponin T (hs-TnT), high-sensitivity troponin I




Figure 1 Time course of the study protocol. Base: baseline; m: months.N-terminal pro-brain natriuretic peptide (NT-proBNP),
serum creatinine (Cr), and the estimated glomerular filtra-
tion rate (eGFR). The levels of hs-TnT, hs-CRP and NT-
proBNP were measured by an electrochemiluminescence
immunoassay, latex-enhanced nephelometry, and an elec-
trochemiluminescence sandwich immunoassay, respec-
tively, according to the manufacturer’s instructions (Roche
Diagnostics, Mannheim, Germany). The hs-TnT assay has
an analytic range of 3–10,000 pg/mL, and the 99th per-
centile cutoff point has been reported as ≥14 pg/mL in
healthy individuals (Giannitsis et al. 2010). The hs-TnI
levels were measured using a chemiluminescence sandwich
immunoassay according to the manufacturer’s instructions
(Siemens Medical Solution Diagnostics, Tarrytown NY,
USA). The hs-TnI assay has an analytic range of 6–
50,000 pg/mL, and the 99th percentile cutoff point has
been reported as ≥40 pg/mL in healthy individuals
(Melanson et al. 2007). Cr was determined by a standard
assay at Jichi Medical University Hospital, and the eGFR
was calculated by the method defined by the Japan
Association of Chronic Kidney Disease (eGFR = 194 ×
Cr−1.094 × age−0.287 × 0.739).
Measurement of echocardiographic parameters
Transthoracic echocardiography was performed using
the iE33 (Philips, Eindhoven, Netherlands) or ARTIDA
(Toshiba Medical Systems Corp., Tochigi, Japan). All
echocardiographic examinations were performed by ex-
perienced cardiologists (K.K. and M.I.) blinded to the
biomarker results. Echocardiographic parameters were
measured in accordance with the guidelines of the
American Society of Echocardiography, and the follow-
ing parameters were assessed: LVEF, left ventricular end-
diastolic diameter (LVDd), mitral E-wave filling velocity/
mitral A-wave filling velocity (E/A), deceleration time
(DcT), peak early diastolic velocity of septal mitral annu-
lus (e’).
LVEF was measured by a modified Simpson’s method
except in one patient. Because this patient’s apical view
was difficult to visualize due to expanders, the LVEF
was measured by the M-mode method using theTrastuzumab
9m 15m12m
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evaluated.
Statistical analysis
All data are expressed as the mean ± SD. Categorical vari-
ables are expressed as percentages and were analyzed
using the χ-square test or Fisher’s exact test. The variables
that were not normally distributed were logarithmically
transformed before the analysis. The comparisons of vari-
ables between group N and group R at the same time
points were done with Student’s t-tests. The comparison
of variables within each group versus the baseline was
performed with a repeated-measures analysis of variance
(ANOVA) followed by Tukey’s test. Pearson’s correlation
was used to test relationship between the changes of
hs-TnT and LVEF. A receiver-operator characteristic (ROC)
curve analysis was applied to determine the cutoff values,
sensitivity and specificity for hs-TnT. A p-value <0.05 was
considered significant. The software program SPSS (version
16.0, Chicago, IL) was used to perform the analysis.Table 1 Baseline characteristics of the 19 patients with HER2-
(R) left ventricular ejection fraction
Group N (n = 10)
Age (yrs) 49 ± 7






Family history of CAD 1 (10%)






Doxorubicin 240 mg/m2 1 (10%)
Epirubicin 300 mg/m2 9 (90%)
Creatinine (mg/dL) 0.55 ± 0.10
eGFR (mL/min/1.73 m2) 93.9 ± 19.0
Echocardiographic parameters
LVEF (%) 68 ± 5
LVDd (mm) 44 ± 3
E/A 1.44 ± 0.41
DcT (ms) 185 ± 26
e’ (cm/s) 11.2 ± 3.2
CAD: coronary artery disease, eGFR: estimated glormerular filtration rate, LVEF: left v
E/A: mitral E-wave filling velocity/mitral A-wave filling velocity, DcT: deceleration timResults
Twenty women were prospectively enrolled in this study;
one patient was excluded from the study because her
chemotherapy protocol was changed because a ma-
lignant lymphoma developed during her breast cancer
treatment. Therefore, 19 patients participated in and
completed the study. They were divided into two groups:
group R was nine patients and group N was 10 patients.
The baseline characteristics are listed in Table 1. The
body mass index values were significantly higher in
group R than in group N (25 ± 3 vs. 22 ± 2, p < 0.05).
There was no significant difference between the two
groups in age, cardiovascular risk factors, side of breast
cancer, radiation use, dose of anthracyclines, or renal
function. In the evaluation of echocardiographic parame-
ters at baseline, there was no significant difference in
LVEF or LVDd between the two groups. The E/A and
e’ values were significantly lower in group R than in group
N (1.00 ± 0.36 vs. 1.44 ± 0.41, p < 0.05 and 7.6 ± 2.0 cm/s
vs. 11.2 ± 3.2 cm/s, p < 0.05, respectively), and DcT waspositive breast cancer who showed normal (N) or reduced
Group R (n = 9) p-value
57 ± 9 0.071












0.50 ± 0.07 0.225
100.5 ± 21.1 0.509
71 ± 3 0.103
44 ± 4 0.756
1.00 ± 0.36 0.028
227 ± 48 0.040
7.6 ± 2.0 0.019
entricular ejection fraction, LVDd: left ventricular end-diastolic diameter,
e, e’: peak early diastolic velocity of septal mitral annulus.
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vs. 185 ± 26 ms, p < 0.05), showing that diastolic function
was more impaired in group R than in group N.
The changes of LVEF at 3, 6, 9, 12 and 15 months ver-
sus baseline are shown in Figure 2. At 9, 12 and
15 months, the LVEF was significantly reduced in group
R compared to group N. In group R, the LVEF was sig-
nificantly reduced at 6, 9, 12, and 15 months compared
to baseline, whereas in group N, the LVEF was not
changed at any time point. The reduction of LVEF at
15 months in group R was 9%.
The changes in cardiac biomarkers are shown in
Table 2. In group R, the hs-TnT levels were significantly
elevated at 3 and 6 months compared to baseline. In
group N, the hs-TnT levels were significantly elevated at
3 months compared to baseline. At 6 months, the hs-
TnT levels in group R were significantly higher than
those in group N (11.0 ± 7.8 pg/mL vs. 4.0 ± 1.4 pg/mL,
p < 0.01).
In group R, the hs-TnI levels were significantly ele-
vated at 3, 6, 12 and 15 months compared to baseline. In
group N, the hs-TnI levels were significantly elevated at
3, 6 and 15 months compared to baseline. There was no
significant difference in hs-TnI levels between the two
groups at any time point.
In both group R and group N, the hs-CRP levels were
significantly elevated at 3 months compared to baseline.
There was no significant difference in hs-CRP levels bet-
ween the two groups at any time point.
In both group R and group N, the NT-proBNP levels
were not significantly different from the baseline levels
at any time point. There was no significant difference



























Figure 2 The changes of left ventricular ejection fraction (ΔLVEF) at 3
(12 m) and 15 months (15 m) versus baseline. Bars represent mean ± SD
at the same time point. *p < 0.05, **p < 0.01 and ***p < 0.001 within each gFigure 3A shows the changes of hs-TnT levels at
6 months significantly correlated with the changes of
LVEF at 15 months (r = −0.56, p < 0.05). The distribution
of hs-TnT levels at 6 months and the ROC curve ana-
lysis of hs-TnT levels at 6 months are shown in Figure 3B
and Figure 3C, respectively. At 6 months, seven of the
nine patients in group R were above the hs-TnT cutoff
value of 5.5 pg/mL, providing 78% sensitivity and 80%
specificity for predicting a reduction of LVEF at
15 months.
Discussion
In this study’s search for predictors of cardiotoxicity in
breast cancer treatment, two findings are notable. First,
elevated hs-TnT levels at 6 months showed a possible
ability to predict a subsequent reduction of LVEF. Se-
cond, the cardiac diastolic function at baseline was more
impaired in group R than in group N.
Cardiac troponins are contractile regulatory peptides,
and with cardiac muscle injury they spill into circulating
blood. They are used as diagnostic biomarkers, especially
for acute coronary syndrome (Donnelly and Millar-Craig
1998; Antman et al. 1996; Apple et al. 2005; Aviles et al.
2002; Lindahl et al. 2000). A high-sensitivity cardiac
troponin assay that can detect low levels of circulating
cardiac troponin has emerged, and its diagnostic and
prognostic accuracy have been reported in several
groups of patients with cardiovascular diseases such as
subclinical cardiovascular diseases (deFilippi et al. 2010),
heart failure (Latini et al. 2007), and stable coronary
artery disease (Omland et al. 2009). This high-sensitivity
troponin assay can measure two kinds of troponin,
troponin T and I. There are several differences between









months (3 m), 6 months (6 m), 9 months (9 m), 12 months
. #p < 0.05, ##p < 0.01 and ###p < 0.001 comparing group N vs. group R
roup vs. baseline with a repeated ANOVA followed by Tukey’s test.
Table 2 Biomarker levels in the HER2-positive breast
cancer patients who showed normal (N) or reduced (R)
left ventricular ejection fraction
Biomarkers Group N (n = 10) Group R (n = 9) p-value
hs-TnT (pg/mL)
Baseline 3.0 3.0
3 months 7.0 ± 5.8** 9.2 ± 6.6* 0.524
6 months 4.0 ± 1.4 11.0 ± 7.8** 0.005
9 months 4.4 ± 2.7 3.6 ± 1.7 0.457
12 months 3.9 ± 1.6 4.9 ± 2.1 0.321
15 months 3.8 ± 1.0 4.4 ± 2.1 0.588
hs-TnI (pg/mL)
Baseline 4.2 ± 4.0 2.8 ± 2.9 0.426
3 months 14.1 ± 7.0*** 19.7 ± 17.3*** 0.649
6 months 10.6 ± 6.7** 21.6 ± 16.4*** 0.246
9 months 7.3 ± 4.8 7.3 ± 6.1 0.621
12 months 7.8 ± 5.9 8.7 ± 5.0 ** 0.634
15 months 10.3 ± 3.5** 10.9 ± 6.4*** 0.788
hs-CRP (mg/dL)
Baseline 0.04 ± 0.02 0.14 ± 0.18 0.112
3 months 0.35 ± 0.27* 0.71 ± 0.64* 0.283
6 months 0.09 ± 0.09 0.11 ± 0.12 0.393
9 months 0.04 ± 0.03 0.05 ± 0.03 0.521
12 months 0.18 ± 0.42 0.08 ± 0.11 0.867
15 months 0.07 ± 0.07 0.85 ± 1.43 0.219
NT-proBNP (pg/mL)
Baseline 66.0 ± 30.5 46.6 ± 43.5 0.071
3 months 56.4 ± 41.9 99.4 ± 76.9 0.337
6 months 45.3 ± 32.8 22.9 ± 13.5 0.112
9 months 39.5 ± 27.4 59.1 ± 27.2 0.093
12 months 59.9 ± 51.4 52.1 ± 28.0 0.886
15 months 61.1 ± 44.0 52.9 ± 26.4 0.795
*p < 0.05, **p < 0.01 and ***p < 0.001 vs. baseline within each group with a
repeated ANOVA followed by Tukey’s test.
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more affected by renal dysfunction than troponin I
(Tsutamoto et al. 2009, 2010; Fehr et al. 2003). A recent
report discussed the differences between the roles of
troponin T and I in the prediction of cardiovascular
events in stable coronary artery disease patients, and in
that report, hs-TnI correlated moderately with hs-TnT
(r = 0.44), and hs-TnI was associated with the incidence
of myocardial infarction (Omland et al. 2013).
Our study is the first to reveal that in group R, both the
hs-TnT levels and the hs-TnI levels not only at 3 months
but also at 6 months were significantly higher than the
corresponding values at baseline. Sawaya et al. (2012) re-
ported the utility of hs-TnI to predict trastuzumab-
induced cardiotoxicity. Their report showed that elevatedhs-TnI levels at 3 months after the completion of anthra-
cycline therapy could predict subsequent cardiotoxicity in
breast cancer patients with adjuvant trastuzumab therapy,
and that hs-TnI with a cutoff value of 30 pg/mL had 48%
sensitivity and 73% specificity for detecting cardiotoxicity.
However, when we look into the report in detail, Sawaya’s
report showed that there were no significant differences in
hs-TnI levels between the group with cardiotoxicity and
the group without cardiotoxicity (32 pg/mL vs. 17 pg/mL,
p = 0.18). In our study, the hs-TnT levels but not the
hs-TnI levels at 6 months were significantly different be-
tween the two groups (11.0 ± 7.8 pg/mL vs. 4.0 ± 1.4 pg/mL,
p < 0.01), and hs-TnT with a cutoff value of 5.5 pg/mL
was predictive of a subsequent reduction of LVEF by
nearly 10% at 15 months, suggesting that hs-TnT could be
a more useful marker to predict cardiotoxicity than
hs-TnI. The molecular size of troponin I is smaller than
that of troponin T, which may facilitate transfer of tropo-
nin I spill into circulating blood, and induce a large va-
riation in the hs-TnI levels of group N. This may indicate
that the leakage of troponin T could more specifically
reflect severe myocardial damage causing reduction of
LVEF.
It is a novel finding that a continuous elevation of
high-sensitivity troponins at 3 and 6 months, not only at
3 months, is correlated with the subsequent develop-
ment of cardiotoxicity. Anthracycline therapy for breast
cancer patients is generally completed at 3 months and
then adjuvant trastuzumab therapy is initiated, and our
results thus suggest that anthracycline-induced cardio-
toxicity remains and trastuzumab-induced myocardial
injury is added at 6 months. Trastuzumab is thought to
inhibit a process of repairing myocardial injury caused
by anthracyclines, leading to a subsequent reduction of
LVEF. This hypothesis is in agreement with the previous
report that the incidence of cardiotoxicity ranges from
2% to 7% when trastuzumab is used as a monotherapy,
and up to 27% when trastuzumab is used with anthracy-
clines as adjuvant therapy (Yeh and Bickford 2009).
Onitilo et al. (2012) showed that elevated hs-CRP
(≥0.3 mg/dL) during trastuzumab therapy had 93% sensi-
tivity and 46% specificity for detecting cardiotoxicity, and
that this value was useful especially for identifying patients
at low risk of developing cardiotoxicity. Our study also
showed that hs-CRP levels were significantly elevated at
3 months compared to baseline, although there were no
significant differences between the two patient groups.
This result is in agreement with Onitilo’s report and might
reflect inflammations due to anthracycline-induced car-
diotoxicity. On the other hand, in our study as well as
in several previous reports (Sawaya et al. 2011, 2012;
Fallah-Rad et al. 2011), the NT-proBNP levels of both
group R and group N patients were not significantly dif-
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Figure 3 The hs-TnT level at 6 months predicts a reduction of LVEF at 15 months. (A) The correlation between the changes of high-sensitivity
troponin T (Δhs-TnT) at 6 months and the changes of left ventricular ejection fraction (ΔLVEF) at 15 months. (B) The dot diagram depicting the
distribution of hs-TnT at 6 months in each group. (C) The ROC curve analysis of hs-TnT at 6 months in both groups. The transverse dot line in (B) and
the arrow in (C) indicate the cutoff point of hs-TnT that provides the maximum value by adding sensitivity to specificity.
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at baseline was more impaired in group R than in group
N. Several studies indicated the utility of decreased longi-
tudinal strain (Sawaya et al. 2011, 2012; Fallah-Rad et al.
2011) and systolic velocity of septal mitral annulus (s’)
(Fallah-Rad et al. 2011) measured by echocardiography for
predicting the cardiotoxicity of adjuvant trastuzumab
therapy. In our study, s’ was not significantly different at
any time point because there was no patient with severe
systolic dysfunction such as reduction of LVEF ≥10% to
<55% (data not shown). However, we showed that at base-
line, the E/A and e’ values were significantly lower and the
DcT was significantly longer in group R than in group N,
suggesting that echocardiographic parameters of diastolic
function could be useful to identify patients at high risk of
developing cardiotoxicity. These findings seem to be sup-
ported by some previous reports showing that diastolic
dysfunction precedes or coexists with systolic dysfunction
for various conditions, such as hypertensive heart diseaseand ischemic heart disease (Vasan and Levy 1996;
Nishimura and Tajik 1997).
Our study has several limitations. First, we used a reduc-
tion of LVEF ≥5% as a surrogate marker of trastuzumab-
induced cardiotoxicity. None of our patients developed
heart failure, and the incidence of trastuzumab-induced
cardiotoxicity was lower than in some other previous
studies. The following points can be given as the reasons.
In our patient population, the prevalence of underlying
diseases such as diabetes, hypertension and obesity were
lower than those in previous studies. These diseases are
known to be conventional cardiac risk factors and have
been reported as robust predictors of anthracycline-
induced cardiotoxicity (Lotrionte et al. 2013). Another
point was that the sensitivity for chemotherapy-induced
cardiotoxicity could be different between races. In ad-
dition, myocardial strains measured by echocardiography
were not assessed in our study. Moreover, our study was
prospective but the population was small. Further studies
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of hs-TnT in trastuzumab-induced cardiotoxicity.
Conclusions
Our study clearly showed that the continuous elevation of
hs-TnT at 3 and 6 months during adjuvant trastuzumab
therapy could predict the subsequent reduction of LVEF,
and diastolic function at baseline was more impaired in
group R than in group N. In breast cancer patients treated
with anthracyclines and trastuzumab, hs-TnT and echo-
cardiographic parameters of diastolic function may be use-
ful to predict cardiotoxicity, and they may be helpful as
guides to avoid adverse cardiac effects.
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